Renal Cell Carcinoma

Findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial support the use of molecularly-directed frontline therapy as means to enrich responses in patients with metastatic clear cell renal cell carcinoma.

“The combination of cabozantinib and atezolizumab demonstrated encouraging clinical activity in previously untreated patients with advanced ccRCC,” said investigator Sumanta Kumar Pal, MD.

The combination use of nivolumab plus ipilimumab, compared with sunitinib, continued to show benefit during a 4-year follow-up in patients with advanced renal cell carcinoma.